Traders were quick to snatch up shares of Tonix Pharmaceuticals Holding Corp. (Nassdaq:TNXP) following the announcement, with ...

The Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for TNX-102 SL (cyclobenzaprine HCL sublingual tablets) for the management of fibromyalgia.

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) shares are trading lower Tuesday after initially jumping after the company ...

(Nasdaq: TNXP) announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for ...

Tonix Pharmaceuticals Holding said the Food and Drug Administration has accepted its application seeking approval of its TNX-102 SL product candidate for the chronic pain condition fibromyalgia.

Tonix Pharma ( (TNXP) ) has provided an announcement.

Tonix Pharmaceuticals (TNXP) announced that the U.S. Food and Drug Administration, FDA, has accepted the filing of its New Drug Application, ...

FDA is expected to assign a Prescription Drug User Fee Act (PDUFA) target action date and announce whether Priority Review ...

Submitted New Drug Application (NDA) to FDA for TNX-102 SL for fibromyalgia based on two statistically significant Phase 3 ...

Tonix Pharmaceuticals Holding Corp (TNXP) stock saw a modest uptick, ending the day at $0.24 which represents a slight increase of $0.01 or 4.35% from the prior close of $0.23. The stock opened at $0.

Equities researchers at StockNews.com assumed coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP – Get Free Report) in a report released on Sunday. The firm set a “sell” rating on the stock.

Tonix Pharmaceuticals Holding Corp (TNXP) stock saw a modest uptick, ending the day at $0.23 which represents a slight increase of $0.03 or 15.00% from the prior close of $0.2. The stock opened at $0.